HR 1632
Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025
Jurisdiction
US Congress
Session
119th Congress (2025-2026)
Last updated at
Jun 13, 2026, 4:11 PM
Take action
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Bill overview
This bill, the Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act, aims to speed up the availability of drugs, biological products, and medical devices in the United States that are already approved for use in other countries. It establishes a process where a product approved abroad can receive ‘reciprocal marketing approval’ in the U.S., provided it meets certain criteria like demonstrating a public health need and safety. The FDA will review these requests, and Congress has the power to override the FDA’s decision if they disagree.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Cosponsor
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.